These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
Filed on Feb. 28, 2025 |
|
Filed on March 1, 2024 |
|
Filed on March 3, 2023 |
|
Filed on March 4, 2022 |
|
Filed on March 5, 2021 |
|
Filed on Feb. 28, 2020 |
Commission
File Number
|
Exact Name of Registrant as Specified in its Charter,
Principal Office Address and Telephone Number
|
State of Incorporation or
Organization
|
I.R.S. Employer
Identification No.
|
001-38646
|
Dow Inc.
|
Delaware
|
30-1128146
|
|
2211 H.H. Dow Way, Midland, MI 48674
|
|
|
|
(989) 636-1000
|
|
|
001-03433
|
The Dow Chemical Company
|
Delaware
|
38-1285128
|
|
2211 H.H. Dow Way, Midland, MI 48674
|
|
|
|
(989) 636-1000
|
|
|
Dow Inc.
|
Large accelerated filer
¨
|
Accelerated
filer
¨
|
Non-accelerated filer
þ
|
Smaller reporting company
¨
|
Emerging growth company
¨
|
The Dow Chemical Company
|
Large accelerated filer
¨
|
Accelerated
filer
¨
|
Non-accelerated filer
þ
|
Smaller reporting company
¨
|
Emerging growth company
¨
|
Registrant
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Dow Inc.
|
Common Stock, par value $0.01 per share
|
DOW
|
New York Stock Exchange
|
|
|
PAGE
|
|
|
|
|
||
|
|
|
Item 1.
|
||
|
|
|
|
The Dow Chemical Company and Subsidiaries:
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
Dow Inc. and The Dow Chemical Company and Subsidiaries:
|
|
|
|
|
|
||
|
|
|
Item 2.
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
Item 3.
|
||
|
|
|
Item 4.
|
||
|
|
|
|
||
|
|
|
Item 1.
|
||
|
|
|
Item 1A.
|
||
|
|
|
Item 4.
|
||
|
|
|
Item 5.
|
||
|
|
|
Item 6.
|
Exhibits
.
|
|
|
|
|
Dow Inc.
The Dow Chemical Company and Subsidiaries
|
PART I – FINANCIAL INFORMATION
|
|
Three Months Ended
|
|||||
In millions (Unaudited)
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Net sales
|
$
|
13,582
|
|
$
|
14,899
|
|
Cost of sales
|
10,707
|
|
11,552
|
|
||
Research and development expenses
|
361
|
|
386
|
|
||
Selling, general and administrative expenses
|
701
|
|
751
|
|
||
Amortization of intangibles
|
154
|
|
159
|
|
||
Restructuring and asset related charges - net
|
232
|
|
165
|
|
||
Integration and separation costs
|
408
|
|
202
|
|
||
Equity in earnings of nonconsolidated affiliates
|
13
|
|
243
|
|
||
Sundry income (expense) - net
|
73
|
|
83
|
|
||
Interest expense and amortization of debt discount
|
247
|
|
270
|
|
||
Income before income taxes
|
858
|
|
1,740
|
|
||
Provision for income taxes
|
272
|
|
363
|
|
||
Net income
|
586
|
|
1,377
|
|
||
Net income attributable to noncontrolling interests
|
45
|
|
35
|
|
||
Net income available for The Dow Chemical Company common stockholder
|
$
|
541
|
|
$
|
1,342
|
|
|
|
|
||||
Depreciation
|
$
|
598
|
|
$
|
621
|
|
Capital expenditures
|
$
|
514
|
|
$
|
423
|
|
|
Three Months Ended
|
|||||
In millions (Unaudited)
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Net income
|
$
|
586
|
|
$
|
1,377
|
|
Other comprehensive income (loss), net of tax
|
|
|
||||
Unrealized gains (losses) on investments
|
67
|
|
(25
|
)
|
||
Cumulative translation adjustments
|
(31
|
)
|
376
|
|
||
Pension and other postretirement benefit plans
|
141
|
|
126
|
|
||
Derivative instruments
|
(75
|
)
|
6
|
|
||
Total other comprehensive income
|
102
|
|
483
|
|
||
Comprehensive income
|
688
|
|
1,860
|
|
||
Comprehensive income attributable to noncontrolling interests, net of tax
|
51
|
|
28
|
|
||
Comprehensive income attributable to The Dow Chemical Company
|
$
|
637
|
|
$
|
1,832
|
|
In millions, except share amounts (Unaudited)
|
Mar 31,
2019 |
Dec 31,
2018 |
||||
Assets
|
|
|
||||
Current Assets
|
|
|
||||
Cash and cash equivalents (variable interest entities restricted - 2019: $109; 2018: $82)
|
$
|
2,969
|
|
$
|
2,669
|
|
Marketable securities
|
101
|
|
100
|
|
||
Accounts and notes receivable:
|
|
|
||||
Trade (net of allowance for doubtful receivables - 2019: $109; 2018: $106)
|
8,428
|
|
8,246
|
|
||
Other
|
3,947
|
|
4,136
|
|
||
Inventories
|
9,508
|
|
9,260
|
|
||
Other current assets
|
708
|
|
852
|
|
||
Total current assets
|
25,661
|
|
25,263
|
|
||
Investments
|
|
|
||||
Investment in nonconsolidated affiliates
|
3,321
|
|
3,823
|
|
||
Other investments (investments carried at fair value - 2019: $1,796; 2018: $1,699)
|
2,737
|
|
2,648
|
|
||
Noncurrent receivables
|
345
|
|
394
|
|
||
Total investments
|
6,403
|
|
6,865
|
|
||
Property
|
|
|
||||
Property
|
61,764
|
|
61,437
|
|
||
Less accumulated depreciation
|
38,272
|
|
37,775
|
|
||
Net property (variable interest entities restricted - 2019: $718; 2018: $734)
|
23,492
|
|
23,662
|
|
||
Other Assets
|
|
|
||||
Goodwill
|
13,812
|
|
13,848
|
|
||
Other intangible assets (net of accumulated amortization - 2019: $5,912; 2018: $5,762)
|
4,743
|
|
4,913
|
|
||
Operating lease right-of-use assets
|
2,584
|
|
—
|
|
||
Deferred income tax assets
|
2,183
|
|
2,031
|
|
||
Deferred charges and other assets
|
859
|
|
796
|
|
||
Total other assets
|
24,181
|
|
21,588
|
|
||
Total Assets
|
$
|
79,737
|
|
$
|
77,378
|
|
Liabilities and Equity
|
|
|
||||
Current Liabilities
|
|
|
||||
Notes payable
|
$
|
317
|
|
$
|
305
|
|
Long-term debt due within one year
|
2,369
|
|
340
|
|
||
Accounts payable:
|
|
|
||||
Trade
|
5,103
|
|
5,378
|
|
||
Other
|
3,176
|
|
3,330
|
|
||
Operating lease liabilities - current
|
477
|
|
—
|
|
||
Income taxes payable
|
699
|
|
791
|
|
||
Accrued and other current liabilities
|
3,232
|
|
3,611
|
|
||
Total current liabilities
|
15,373
|
|
13,755
|
|
||
Long-Term Debt (variable interest entities nonrecourse - 2019: $43; 2018: $75)
|
17,160
|
|
19,254
|
|
||
Other Noncurrent Liabilities
|
|
|
||||
Deferred income tax liabilities
|
721
|
|
664
|
|
||
Pension and other postretirement benefits - noncurrent
|
9,103
|
|
9,226
|
|
||
Asbestos-related liabilities - noncurrent
|
1,133
|
|
1,142
|
|
||
Operating lease liabilities - noncurrent
|
2,126
|
|
—
|
|
||
Other noncurrent obligations
|
5,975
|
|
5,368
|
|
||
Total other noncurrent liabilities
|
19,058
|
|
16,400
|
|
||
Stockholders’ Equity
|
|
|
||||
Common stock (authorized and issued 100 shares of $0.01 par value each)
|
—
|
|
—
|
|
||
Additional paid-in capital
|
7,153
|
|
7,042
|
|
||
Retained earnings
|
29,701
|
|
29,808
|
|
||
Accumulated other comprehensive loss
|
(9,783
|
)
|
(9,885
|
)
|
||
Unearned ESOP shares
|
(105
|
)
|
(134
|
)
|
||
The Dow Chemical Company’s stockholders’ equity
|
26,966
|
|
26,831
|
|
||
Noncontrolling interests
|
1,180
|
|
1,138
|
|
||
Total equity
|
28,146
|
|
27,969
|
|
||
Total Liabilities and Equity
|
$
|
79,737
|
|
$
|
77,378
|
|
|
Three Months Ended
|
|||||
In millions (Unaudited)
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Operating Activities
|
|
|
||||
Net income
|
$
|
586
|
|
$
|
1,377
|
|
Adjustments to reconcile net income to net cash provided by (used for) operating activities:
|
|
|
||||
Depreciation and amortization
|
840
|
|
837
|
|
||
Credit for deferred income tax
|
(89
|
)
|
(67
|
)
|
||
Earnings of nonconsolidated affiliates less than dividends received
|
750
|
|
287
|
|
||
Net periodic pension benefit cost
|
62
|
|
110
|
|
||
Pension contributions
|
(103
|
)
|
(308
|
)
|
||
Net (gain) loss on sales of assets, businesses and investments
|
12
|
|
(33
|
)
|
||
Restructuring and asset related charges - net
|
232
|
|
165
|
|
||
Other net loss
|
39
|
|
98
|
|
||
Changes in assets and liabilities, net of effects of acquired and divested companies:
|
|
|
||||
Accounts and notes receivable
|
(58
|
)
|
(1,524
|
)
|
||
Inventories
|
(266
|
)
|
(1,239
|
)
|
||
Accounts payable
|
(468
|
)
|
823
|
|
||
Other assets and liabilities, net
|
(111
|
)
|
(684
|
)
|
||
Cash provided by (used for) operating activities
|
1,426
|
|
(158
|
)
|
||
Investing Activities
|
|
|
||||
Capital expenditures
|
(514
|
)
|
(423
|
)
|
||
Investment in gas field developments
|
(25
|
)
|
(28
|
)
|
||
Proceeds from sales of property and businesses, net of cash divested
|
25
|
|
17
|
|
||
Proceeds from sale of ownership interests in nonconsolidated affiliates
|
21
|
|
—
|
|
||
Purchases of investments
|
(173
|
)
|
(557
|
)
|
||
Proceeds from sales and maturities of investments
|
180
|
|
454
|
|
||
Proceeds from interests in trade accounts receivable conduits
|
—
|
|
445
|
|
||
Cash used for investing activities
|
(486
|
)
|
(92
|
)
|
||
Financing Activities
|
|
|
||||
Changes in short-term notes payable
|
(17
|
)
|
293
|
|
||
Payments on long-term debt
|
(80
|
)
|
(54
|
)
|
||
Proceeds from issuance of parent company stock
|
28
|
|
63
|
|
||
Employee taxes paid for share-based payment arrangements
|
(54
|
)
|
(77
|
)
|
||
Distributions to noncontrolling interests
|
(9
|
)
|
(24
|
)
|
||
Dividends paid to parent
|
(535
|
)
|
(1,057
|
)
|
||
Other financing activities, net
|
—
|
|
3
|
|
||
Cash used for financing activities
|
(667
|
)
|
(853
|
)
|
||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
30
|
|
100
|
|
||
Summary
|
|
|
||||
Increase (Decrease) in cash, cash equivalents and restricted cash
|
303
|
|
(1,003
|
)
|
||
Cash, cash equivalents and restricted cash at beginning of period
|
2,709
|
|
6,207
|
|
||
Cash, cash equivalents and restricted cash at end of period
|
$
|
3,012
|
|
$
|
5,204
|
|
Less: Restricted cash and cash equivalents, included in "Other current assets"
|
43
|
|
18
|
|
||
Cash and cash equivalents at end of period
|
$
|
2,969
|
|
$
|
5,186
|
|
|
Three Months Ended
|
|||||
In millions (Unaudited)
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Common Stock
|
|
|
||||
Balance at beginning and end of period
|
$
|
—
|
|
$
|
—
|
|
Additional Paid-in Capital
|
|
|
||||
Balance at beginning of period
|
7,042
|
|
6,553
|
|
||
Issuance of parent company stock
|
28
|
|
63
|
|
||
Stock-based compensation and allocation of ESOP shares
|
83
|
|
142
|
|
||
Balance at end of period
|
7,153
|
|
6,758
|
|
||
Retained Earnings
|
|
|
||||
Balance at beginning of period
|
29,808
|
|
28,050
|
|
||
Net income available for The Dow Chemical Company common stockholder
|
541
|
|
1,342
|
|
||
Dividends to parent
|
(535
|
)
|
(1,057
|
)
|
||
Adoption of accounting standards (Notes 1, 2 and 6)
|
(111
|
)
|
(68
|
)
|
||
Other
|
(2
|
)
|
(6
|
)
|
||
Balance at end of period
|
29,701
|
|
28,261
|
|
||
Accumulated Other Comprehensive Loss
|
|
|
||||
Balance at beginning of period
|
(9,885
|
)
|
(8,591
|
)
|
||
Other comprehensive income
|
102
|
|
483
|
|
||
Adoption of accounting standards (Note 1)
|
—
|
|
20
|
|
||
Balance at end of period
|
(9,783
|
)
|
(8,088
|
)
|
||
Unearned ESOP Shares
|
|
|
||||
Balance at beginning of period
|
(134
|
)
|
(189
|
)
|
||
Allocation of ESOP shares
|
29
|
|
39
|
|
||
Balance at end of period
|
(105
|
)
|
(150
|
)
|
||
The Dow Chemical Company's stockholders' equity
|
26,966
|
|
26,781
|
|
||
Noncontrolling Interests
|
1,180
|
|
1,190
|
|
||
Total Equity
|
$
|
28,146
|
|
$
|
27,971
|
|
Dow Inc.
The Dow Chemical Company and Subsidiaries
|
Note
|
|
Page
|
1
|
||
2
|
||
3
|
||
4
|
||
5
|
||
6
|
||
7
|
||
8
|
||
9
|
||
10
|
||
11
|
||
12
|
||
13
|
||
14
|
||
15
|
||
16
|
||
17
|
||
18
|
||
19
|
Net Trade Sales by Principal Product Group
|
Three Months Ended
|
|||||
In millions
|
Mar 31, 2019
|
Mar 31, 2018
|
||||
Coatings & Performance Monomers
|
$
|
904
|
|
$
|
954
|
|
Consumer Solutions
|
1,365
|
|
1,363
|
|
||
Crop Protection
|
1,124
|
|
1,122
|
|
||
Electronics & Imaging
|
625
|
|
627
|
|
||
Hydrocarbons & Energy
|
1,380
|
|
1,779
|
|
||
Industrial Biosciences
|
119
|
|
135
|
|
||
Industrial Solutions
1
|
1,104
|
|
1,156
|
|
||
Nutrition & Health
|
152
|
|
156
|
|
||
Packaging and Specialty Plastics
|
3,410
|
|
3,854
|
|
||
Polyurethanes & CAV
1
|
2,297
|
|
2,557
|
|
||
Safety & Construction
|
424
|
|
444
|
|
||
Seed
|
323
|
|
371
|
|
||
Transportation & Advanced Polymers
|
284
|
|
304
|
|
||
Corporate
|
69
|
|
73
|
|
||
Other
|
2
|
|
4
|
|
||
Total
|
$
|
13,582
|
|
$
|
14,899
|
|
Net Trade Sales by Geographic Region
|
Three Months Ended
|
|||||
In millions
|
Mar 31, 2019
|
Mar 31, 2018
|
||||
U.S. & Canada
|
$
|
4,884
|
|
$
|
5,468
|
|
EMEA
1
|
4,211
|
|
4,765
|
|
||
Asia Pacific
|
3,202
|
|
3,256
|
|
||
Latin America
|
1,285
|
|
1,410
|
|
||
Total
|
$
|
13,582
|
|
$
|
14,899
|
|
Contract Balances
|
Mar 31, 2019
|
Dec 31, 2018
|
||||
In millions
|
||||||
Accounts and notes receivable - Trade
|
$
|
8,428
|
|
$
|
8,246
|
|
Contract assets - current
1
|
$
|
26
|
|
$
|
37
|
|
Contract assets - noncurrent
2
|
$
|
47
|
|
$
|
47
|
|
Contract liabilities - current
3
|
$
|
233
|
|
$
|
165
|
|
Contract liabilities - noncurrent
4
|
$
|
1,739
|
|
$
|
1,390
|
|
1.
|
Included in "Other current assets" in the consolidated balance sheets.
|
2.
|
Included in "Deferred charges and other assets" in the consolidated balance sheets.
|
3.
|
Included in "Accrued and other current liabilities" in the consolidated balance sheets.
|
4.
|
Included in "Other noncurrent obligations" in the consolidated balance sheets.
|
DowDuPont Agriculture Division Program
|
Severance and Related Benefit Costs
|
Asset Write-downs and Write-offs
|
Total
|
||||||
In millions
|
|||||||||
2018 restructuring charges
|
$
|
24
|
|
$
|
1
|
|
$
|
25
|
|
Charges against the reserve
|
—
|
|
(1
|
)
|
(1
|
)
|
|||
Cash payments
|
(1
|
)
|
—
|
|
(1
|
)
|
|||
Reserve balance at Dec 31, 2018
|
$
|
23
|
|
$
|
—
|
|
$
|
23
|
|
Adjustments to the reserve
|
(4
|
)
|
—
|
|
(4
|
)
|
|||
Cash payments
|
(8
|
)
|
—
|
|
(8
|
)
|
|||
Reserve balance at Mar 31, 2019
|
$
|
11
|
|
$
|
—
|
|
$
|
11
|
|
DowDuPont Synergy Program
|
Severance and Related Benefit Costs
|
Asset Write-downs and Write-offs
|
Costs Associated with Exit and Disposal Activities
|
Total
|
||||||||
In millions
|
||||||||||||
Reserve balance at Dec 31, 2018
|
$
|
262
|
|
$
|
—
|
|
$
|
65
|
|
$
|
327
|
|
2019 restructuring charges
|
72
|
|
100
|
|
52
|
|
224
|
|
||||
Charges against the reserve
|
—
|
|
(100
|
)
|
—
|
|
(100
|
)
|
||||
Cash payments
|
(97
|
)
|
—
|
|
(29
|
)
|
(126
|
)
|
||||
Reserve balance at Mar 31, 2019
|
$
|
237
|
|
$
|
—
|
|
$
|
88
|
|
$
|
325
|
|
Inventories
|
Mar 31, 2019
|
Dec 31, 2018
|
||||
In millions
|
||||||
Finished goods
|
$
|
5,703
|
|
$
|
5,640
|
|
Work in process
|
2,239
|
|
2,214
|
|
||
Raw materials
|
940
|
|
941
|
|
||
Supplies
|
891
|
|
880
|
|
||
Total
|
$
|
9,773
|
|
$
|
9,675
|
|
Adjustment of inventories to a LIFO basis
|
(265
|
)
|
(415
|
)
|
||
Total inventories
|
$
|
9,508
|
|
$
|
9,260
|
|
Investments in Nonconsolidated Affiliates
|
Mar 31, 2019
|
Dec 31, 2018
|
||||
In millions
|
||||||
Investment in nonconsolidated affiliates
|
$
|
3,321
|
|
$
|
3,823
|
|
Other noncurrent obligations
|
(870
|
)
|
(495
|
)
|
||
Net investment in nonconsolidated affiliates
|
$
|
2,451
|
|
$
|
3,328
|
|
Investment in the HSC Group
|
|
Investment
|
|||||
In millions
|
Balance Sheet Classification
|
Mar 31, 2019
|
Dec 31, 2018
|
||||
Hemlock Semiconductor L.L.C.
|
Other noncurrent obligations
|
$
|
(658
|
)
|
$
|
(495
|
)
|
DC HSC Holdings LLC
|
Investment in nonconsolidated affiliates
|
$
|
485
|
|
$
|
535
|
|
Goodwill
|
|
||
In millions
|
|||
Net goodwill at Dec 31, 2018
|
$
|
13,848
|
|
Foreign currency impact
|
(36
|
)
|
|
Net goodwill at Mar 31, 2019
|
$
|
13,812
|
|
Other Intangible Assets
|
Mar 31, 2019
|
Dec 31, 2018
|
||||||||||||||||
In millions
|
Gross
Carrying
Amount
|
Accum
Amort
|
Net
|
Gross
Carrying
Amount
|
Accum
Amort
|
Net
|
||||||||||||
Intangible assets with finite lives:
|
|
|
|
|
|
|
||||||||||||
Developed technology
|
$
|
3,253
|
|
$
|
(1,996
|
)
|
$
|
1,257
|
|
$
|
3,255
|
|
$
|
(1,934
|
)
|
$
|
1,321
|
|
Software
|
1,539
|
|
(900
|
)
|
639
|
|
1,529
|
|
(876
|
)
|
653
|
|
||||||
Trademarks/tradenames
|
680
|
|
(638
|
)
|
42
|
|
688
|
|
(631
|
)
|
57
|
|
||||||
Customer-related
|
4,898
|
|
(2,211
|
)
|
2,687
|
|
4,911
|
|
(2,151
|
)
|
2,760
|
|
||||||
Other
|
236
|
|
(167
|
)
|
69
|
|
243
|
|
(170
|
)
|
73
|
|
||||||
Total other intangible assets, finite lives
|
$
|
10,606
|
|
$
|
(5,912
|
)
|
$
|
4,694
|
|
$
|
10,626
|
|
$
|
(5,762
|
)
|
$
|
4,864
|
|
In-process research and development
|
49
|
|
—
|
|
49
|
|
49
|
|
—
|
|
49
|
|
||||||
Total other intangible assets
|
$
|
10,655
|
|
$
|
(5,912
|
)
|
$
|
4,743
|
|
$
|
10,675
|
|
$
|
(5,762
|
)
|
$
|
4,913
|
|
Amortization Expense
|
Three Months Ended
|
|||||
In millions
|
Mar 31, 2019
|
Mar 31, 2018
|
||||
Other intangible assets, excluding software
|
$
|
154
|
|
$
|
159
|
|
Software, included in “Cost of sales”
|
$
|
25
|
|
$
|
23
|
|
Estimated Amortization Expense
|
|||
In millions
|
|||
2019
|
$
|
659
|
|
2020
|
$
|
623
|
|
2021
|
$
|
594
|
|
2022
|
$
|
525
|
|
2023
|
$
|
492
|
|
2024
|
$
|
456
|
|
Cash Proceeds
|
Three Months Ended
|
|||||
In millions
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Interests in conduits
1
|
$
|
—
|
|
$
|
445
|
|
1.
|
Presented in "Investing Activities" in the consolidated statements of cash flows.
|
Notes Payable
|
Mar 31,
2019 |
Dec 31,
2018 |
||||
In millions
|
||||||
Commercial paper
|
$
|
—
|
|
$
|
10
|
|
Notes payable to banks and other lenders
|
317
|
|
295
|
|
||
Total notes payable
|
$
|
317
|
|
$
|
305
|
|
Period-end average interest rates
|
12.09
|
%
|
8.61
|
%
|
Long-Term Debt
|
2019 Average Rate
|
Mar 31,
2019 |
2018
Average
Rate
|
Dec 31,
2018 |
||||||
In millions
|
||||||||||
Promissory notes and debentures:
|
|
|
|
|
||||||
Final maturity 2019
|
9.80
|
%
|
$
|
7
|
|
9.80
|
%
|
$
|
7
|
|
Final maturity 2020
|
4.46
|
%
|
1,547
|
|
4.46
|
%
|
1,547
|
|
||
Final maturity 2021
|
4.71
|
%
|
1,424
|
|
4.71
|
%
|
1,424
|
|
||
Final maturity 2022
|
3.50
|
%
|
1,372
|
|
3.50
|
%
|
1,373
|
|
||
Final maturity 2023
|
7.64
|
%
|
325
|
|
7.64
|
%
|
325
|
|
||
Final maturity 2024
|
3.50
|
%
|
896
|
|
3.50
|
%
|
896
|
|
||
Final maturity 2025 and thereafter
|
5.98
|
%
|
7,963
|
|
5.98
|
%
|
7,963
|
|
||
Other facilities:
|
|
|
|
|
||||||
U.S. dollar loans, various rates and maturities
|
3.52
|
%
|
4,533
|
|
3.59
|
%
|
4,533
|
|
||
Foreign currency loans, various rates and maturities
|
3.19
|
%
|
714
|
|
3.21
|
%
|
713
|
|
||
Medium-term notes, varying maturities through 2025
|
3.33
|
%
|
703
|
|
3.26
|
%
|
778
|
|
||
Finance lease obligations
|
|
369
|
|
|
369
|
|
||||
Unamortized debt discount and issuance costs
|
|
(324
|
)
|
|
(334
|
)
|
||||
Long-term debt due within one year
1
|
|
(2,369
|
)
|
|
(340
|
)
|
||||
Long-term debt
|
|
$
|
17,160
|
|
|
$
|
19,254
|
|
1.
|
Presented net of current portion of unamortized debt issuance costs.
|
Maturities of Long-Term Debt for Next Five Years at Mar 31, 2019
|
|||
In millions
|
|||
2019
1
|
$
|
2,307
|
|
2020
|
$
|
1,839
|
|
2021
2
|
$
|
4,249
|
|
2022
|
$
|
1,507
|
|
2023
|
$
|
500
|
|
2024
|
$
|
968
|
|
1.
|
Includes
$2.0 billion
of current maturities related to the Dow Silicones term loan facility, repaid on April 5, 2019.
|
2.
|
Assumes the option to extend will be exercised for
$2.5 billion
of the Dow Silicones term loan facility.
|
Committed and Available Credit Facilities at Mar 31, 2019
|
||||||||
In millions
|
Committed Credit
|
Credit Available
|
Maturity Date
|
Interest
|
||||
Five Year Competitive Advance and Revolving Credit Facility
|
$
|
5,000
|
|
$
|
5,000
|
|
October 2023
|
Floating rate
|
Term Loan Facility
1
|
2,000
|
|
—
|
|
April 2019
|
Floating rate
|
||
Term Loan Facility
2
|
2,500
|
|
—
|
|
December 2021
|
Floating rate
|
||
North American Securitization Facility
|
800
|
|
800
|
|
September 2019
|
Floating rate
|
||
European Securitization Facility
3
|
450
|
|
450
|
|
October 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
100
|
|
100
|
|
October 2019
|
Floating rate
|
||
Bilateral Revolving Credit Facility
4
|
100
|
|
100
|
|
March 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
100
|
|
100
|
|
March 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
280
|
|
280
|
|
March 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
100
|
|
100
|
|
March 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
200
|
|
200
|
|
March 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
200
|
|
200
|
|
May 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
200
|
|
200
|
|
July 2020
|
Floating rate
|
||
Bilateral Revolving Credit Facility
|
100
|
|
100
|
|
August 2020
|
Floating rate
|
||
Total committed and available credit facilities
|
$
|
12,130
|
|
$
|
7,630
|
|
|
|
1.
|
Dow Silicones voluntarily repaid
$2.0 billion
of principal on April 5, 2019.
|
2.
|
Assumes the option to extend the Dow Silicones term loan facility will be exercised.
|
3.
|
Equivalent to
Euro 400 million
.
|
4.
|
On March 9, 2019, TDCC renewed a
$100 million
Bilateral Revolving Credit Facility agreement, which has a maturity date in March 2020 and provides for interest at floating rates, as defined in the agreement.
|
Guarantees
|
Mar 31, 2019
|
Dec 31, 2018
|
||||||||||||
In millions
|
Final
Expiration
|
Maximum
Future Payments
|
Recorded
Liability
|
Final
Expiration
|
Maximum
Future Payments
|
Recorded
Liability
|
||||||||
Guarantees
|
2023
|
$
|
4,514
|
|
$
|
15
|
|
2023
|
$
|
4,523
|
|
$
|
25
|
|
Lease Cost
|
Three Months Ended
Mar 31, 2019 |
||
In millions
|
|||
Operating lease cost
|
$
|
147
|
|
Finance lease cost
|
|
||
Amortization of right-of-use assets - finance
|
6
|
|
|
Interest on lease liabilities - finance
|
6
|
|
|
Total finance lease cost
|
$
|
12
|
|
Short-term lease cost
|
55
|
|
|
Variable lease cost
|
85
|
|
|
Sublease income
|
(1
|
)
|
|
Total lease cost
|
$
|
298
|
|
Other Lease Information
|
Three Months Ended
Mar 31, 2019 |
||
In millions
|
|||
Cash paid for amounts included in the measurement of lease liabilities:
|
|
||
Operating cash flows from operating leases
|
$
|
154
|
|
Operating cash flows from finance leases
|
$
|
6
|
|
Financing cash flows from finance leases
|
$
|
3
|
|
Lease Position
|
Balance Sheet Classification
|
Mar 31, 2019
|
||
In millions
|
||||
Right-of-use assets obtained in exchange for lease obligations:
|
|
|
||
Operating leases
1
|
|
$
|
2,714
|
|
Assets
|
|
|
||
Operating lease assets
|
Operating lease right-of-use assets
|
$
|
2,584
|
|
Finance lease assets
|
Property
|
437
|
|
|
Finance lease amortization
|
Accumulated depreciation
|
(143
|
)
|
|
Total lease assets
|
|
$
|
2,878
|
|
Liabilities
|
|
|
||
Current
|
|
|
||
Operating
|
Operating lease liabilities - current
|
$
|
477
|
|
Finance
|
Long-term debt due within one year
|
20
|
|
|
Noncurrent
|
|
|
||
Operating
|
Operating lease liabilities - noncurrent
|
2,126
|
|
|
Finance
|
Long-Term Debt
|
349
|
|
|
Total lease liabilities
|
|
$
|
2,972
|
|
1.
|
Includes
$2.7 billion
related to the adoption of Topic 842. See Note
2
for additional information.
|
Lease Term and Discount Rate
|
Mar 31, 2019
|
|
Weighted-average remaining lease term
|
|
|
Operating leases
|
8.7 years
|
|
Finance leases
|
18.7 years
|
|
Weighted-average discount rate
|
|
|
Operating leases
|
4.12
|
%
|
Finance leases
|
6.98
|
%
|
Maturities of Lease Liabilities at Mar 31, 2019
|
Operating Leases
|
Finance Leases
|
||||
In millions
|
||||||
2019
|
$
|
437
|
|
$
|
38
|
|
2020
|
515
|
|
48
|
|
||
2021
|
421
|
|
46
|
|
||
2022
|
343
|
|
44
|
|
||
2023
|
291
|
|
71
|
|
||
2024 and thereafter
|
1,157
|
|
309
|
|
||
Total future undiscounted lease payments
|
$
|
3,164
|
|
$
|
556
|
|
Less imputed interest
|
561
|
|
187
|
|
||
Total present value of lease liabilities
|
$
|
2,603
|
|
$
|
369
|
|
Minimum Lease Commitments at Dec 31, 2018
|
|
||
In millions
|
|
||
2019
|
$
|
412
|
|
2020
|
369
|
|
|
2021
|
328
|
|
|
2022
|
297
|
|
|
2023
|
253
|
|
|
2024 and thereafter
|
978
|
|
|
Total
|
$
|
2,637
|
|
Lease Guarantees
|
March 31, 2019
|
December 31, 2018
|
||||||||||||
In millions
|
Final Expiration
|
Maximum Future Payments
|
Recorded Liability
|
Final Expiration
|
Maximum Future Payments
|
Recorded Liability
|
||||||||
Residual value guarantees
|
2028
|
$
|
885
|
|
$
|
—
|
|
2028
|
$
|
885
|
|
$
|
130
|
|
Accumulated Other Comprehensive Loss
|
Unrealized Gains (Losses) on Investments
|
Cumulative Translation Adj
|
Pension and Other Postretire Benefits
|
Derivative Instruments
|
Total Accum Other Comp Loss
|
||||||||||
In millions
|
|||||||||||||||
Balance at Jan 1, 2018
|
$
|
17
|
|
$
|
(1,481
|
)
|
$
|
(6,998
|
)
|
$
|
(109
|
)
|
$
|
(8,571
|
)
|
Other comprehensive income (loss) before reclassifications
|
(26
|
)
|
376
|
|
—
|
|
(16
|
)
|
334
|
|
|||||
Amounts reclassified from accumulated other comprehensive income (loss)
|
1
|
|
—
|
|
126
|
|
22
|
|
149
|
|
|||||
Net other comprehensive income (loss)
|
$
|
(25
|
)
|
$
|
376
|
|
$
|
126
|
|
$
|
6
|
|
$
|
483
|
|
Balance at Mar 31, 2018
|
$
|
(8
|
)
|
$
|
(1,105
|
)
|
$
|
(6,872
|
)
|
$
|
(103
|
)
|
$
|
(8,088
|
)
|
|
|
|
|
|
|
||||||||||
Balance at Jan 1, 2019
|
$
|
(51
|
)
|
$
|
(1,813
|
)
|
$
|
(7,965
|
)
|
$
|
(56
|
)
|
$
|
(9,885
|
)
|
Other comprehensive income (loss) before reclassifications
|
68
|
|
(13
|
)
|
—
|
|
(68
|
)
|
(13
|
)
|
|||||
Amounts reclassified from accumulated other comprehensive loss
|
(1
|
)
|
(18
|
)
|
141
|
|
(7
|
)
|
115
|
|
|||||
Net other comprehensive income (loss)
|
$
|
67
|
|
$
|
(31
|
)
|
$
|
141
|
|
$
|
(75
|
)
|
$
|
102
|
|
Balance at Mar 31, 2019
|
$
|
16
|
|
$
|
(1,844
|
)
|
$
|
(7,824
|
)
|
$
|
(131
|
)
|
$
|
(9,783
|
)
|
Tax Benefit (Expense)
1
|
Three Months Ended
|
|||||
In millions
|
Mar 31, 2019
|
Mar 31, 2018
|
||||
Unrealized gains (losses) on investments
|
$
|
(18
|
)
|
$
|
6
|
|
Cumulative translation adjustments
|
(1
|
)
|
5
|
|
||
Pension and other postretirement benefit plans
|
(25
|
)
|
(28
|
)
|
||
Derivative instruments
|
27
|
|
3
|
|
||
Tax expense from income taxes related to other comprehensive income (loss) items
|
$
|
(17
|
)
|
$
|
(14
|
)
|
1.
|
Prior period amounts were updated to conform with the current year presentation.
|
Reclassifications Out of Accumulated Other Comprehensive Loss
|
Three Months Ended
|
Consolidated Statements of Income Classification
|
|||||
Mar 31, 2019
|
Mar 31, 2018
|
||||||
In millions
|
|||||||
Unrealized (gains) losses on investments
|
$
|
(1
|
)
|
$
|
2
|
|
See (1) below
|
Tax benefit
|
—
|
|
(1
|
)
|
See (2) below
|
||
After tax
|
$
|
(1
|
)
|
$
|
1
|
|
|
Cumulative translation adjustments
|
$
|
(18
|
)
|
$
|
—
|
|
See (3) below
|
Pension and other postretirement benefit plans
|
$
|
166
|
|
$
|
154
|
|
See (4) below
|
Tax benefit
|
(25
|
)
|
(28
|
)
|
See (2) below
|
||
After tax
|
$
|
141
|
|
$
|
126
|
|
|
Derivative instruments
|
$
|
(7
|
)
|
$
|
27
|
|
See (5) below
|
Tax benefit
|
—
|
|
(5
|
)
|
See (2) below
|
||
After tax
|
$
|
(7
|
)
|
$
|
22
|
|
|
Total reclassifications for the period, after tax
|
$
|
115
|
|
$
|
149
|
|
|
1.
|
"Net sales" and "Sundry income (expense) - net."
|
2.
|
"Provision for income taxes."
|
3.
|
"Sundry income (expense) - net."
|
4.
|
These AOCL components are included in the computation of net periodic benefit cost of TDCC's defined benefit pension and other postretirement benefit plans. See Note
14
for additional information.
|
5.
|
"Cost of sales," "Sundry income (expense) - net" and "Interest expense and amortization of debt discount."
|
Noncontrolling Interests
|
Three Months Ended
|
|||||
In millions
|
Mar 31, 2019
|
Mar 31, 2018
|
||||
Balance at beginning of period
|
$
|
1,138
|
|
$
|
1,186
|
|
Net income attributable to noncontrolling interests
|
45
|
|
35
|
|
||
Distributions to noncontrolling interests
|
(9
|
)
|
(24
|
)
|
||
Cumulative translation adjustments
|
7
|
|
(6
|
)
|
||
Other
|
(1
|
)
|
(1
|
)
|
||
Balance at end of period
|
$
|
1,180
|
|
$
|
1,190
|
|
Net Periodic Benefit Cost for All Significant Plans
|
Three Months Ended
|
|||||
In millions
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Defined Benefit Pension Plans:
|
|
|
||||
Service cost
|
$
|
112
|
|
$
|
133
|
|
Interest cost
|
241
|
|
218
|
|
||
Expected return on plan assets
|
(417
|
)
|
(406
|
)
|
||
Amortization of prior service credit
|
(6
|
)
|
(6
|
)
|
||
Amortization of net loss
|
132
|
|
171
|
|
||
Net periodic benefit cost
|
$
|
62
|
|
$
|
110
|
|
|
|
|
||||
Other Postretirement Benefits:
|
|
|
||||
Service cost
|
$
|
2
|
|
$
|
3
|
|
Interest cost
|
14
|
|
11
|
|
||
Amortization of net gain
|
(6
|
)
|
(6
|
)
|
||
Net periodic benefit cost
|
$
|
10
|
|
$
|
8
|
|
Fair Value of Financial Instruments
|
Mar 31, 2019
|
Dec 31, 2018
|
||||||||||||||||||||||
In millions
|
Cost
|
Gain
|
Loss
|
Fair Value
|
Cost
|
Gain
|
Loss
|
Fair Value
|
||||||||||||||||
Cash equivalents
|
$
|
345
|
|
$
|
—
|
|
$
|
—
|
|
$
|
345
|
|
$
|
566
|
|
$
|
—
|
|
$
|
—
|
|
$
|
566
|
|
Marketable securities
|
$
|
101
|
|
$
|
—
|
|
$
|
—
|
|
$
|
101
|
|
$
|
100
|
|
$
|
—
|
|
$
|
—
|
|
$
|
100
|
|
Other investments:
|
|
|
|
|
|
|
|
|
||||||||||||||||
Debt securities:
|
|
|
|
|
|
|
|
|
||||||||||||||||
Government debt
1
|
$
|
694
|
|
$
|
17
|
|
$
|
(9
|
)
|
$
|
702
|
|
$
|
714
|
|
$
|
9
|
|
$
|
(23
|
)
|
$
|
700
|
|
Corporate bonds
|
1,051
|
|
43
|
|
(21
|
)
|
1,073
|
|
1,026
|
|
20
|
|
(63
|
)
|
983
|
|
||||||||
Total debt securities
|
$
|
1,745
|
|
$
|
60
|
|
$
|
(30
|
)
|
$
|
1,775
|
|
$
|
1,740
|
|
$
|
29
|
|
$
|
(86
|
)
|
$
|
1,683
|
|
Equity securities
2
|
16
|
|
5
|
|
—
|
|
21
|
|
16
|
|
1
|
|
(1
|
)
|
16
|
|
||||||||
Total other investments
|
$
|
1,761
|
|
$
|
65
|
|
$
|
(30
|
)
|
$
|
1,796
|
|
$
|
1,756
|
|
$
|
30
|
|
$
|
(87
|
)
|
$
|
1,699
|
|
Total cash equivalents, marketable securities and other investments
|
$
|
2,207
|
|
$
|
65
|
|
$
|
(30
|
)
|
$
|
2,242
|
|
$
|
2,422
|
|
$
|
30
|
|
$
|
(87
|
)
|
$
|
2,365
|
|
Long-term debt including debt due within one year
3
|
$
|
(19,529
|
)
|
$
|
84
|
|
$
|
(1,405
|
)
|
$
|
(20,850
|
)
|
$
|
(19,594
|
)
|
$
|
351
|
|
$
|
(971
|
)
|
$
|
(20,214
|
)
|
Derivatives relating to:
|
|
|
|
|
|
|
|
|
||||||||||||||||
Interest rates
|
$
|
—
|
|
$
|
—
|
|
$
|
(181
|
)
|
$
|
(181
|
)
|
$
|
—
|
|
$
|
—
|
|
$
|
(64
|
)
|
$
|
(64
|
)
|
Foreign currency
|
—
|
|
86
|
|
(14
|
)
|
72
|
|
—
|
|
120
|
|
(43
|
)
|
77
|
|
||||||||
Commodities
4
|
—
|
|
88
|
|
(147
|
)
|
(59
|
)
|
—
|
|
91
|
|
(178
|
)
|
(87
|
)
|
||||||||
Total derivatives
|
$
|
—
|
|
$
|
174
|
|
$
|
(342
|
)
|
$
|
(168
|
)
|
$
|
—
|
|
$
|
211
|
|
$
|
(285
|
)
|
$
|
(74
|
)
|
2.
|
Equity securities with a readily determinable fair value.
|
3.
|
Cost includes fair value hedge adjustments of
$17 million
at
March 31, 2019
and
$18 million
at
December 31, 2018
on
$2,290 million
of debt at
March 31, 2019
and
December 31, 2018
.
|
4.
|
Presented net of cash collateral where master netting arrangements allow.
|
Investing Results
|
Three Months Ended
|
|||||
In millions
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Proceeds from sales of available-for-sale securities
|
$
|
159
|
|
$
|
348
|
|
Gross realized gains
|
$
|
6
|
|
$
|
7
|
|
Gross realized losses
|
$
|
(5
|
)
|
$
|
(9
|
)
|
Fair Value of Derivative Instruments
|
Mar 31, 2019
|
|||||||||
In millions
|
Balance Sheet Classification
|
Gross
|
Counterparty and Cash Collateral Netting
1
|
Net Amounts Included in the Consolidated Balance Sheet
|
||||||
Asset derivatives:
|
|
|
|
|
||||||
Derivatives designated as hedging instruments:
|
|
|
|
|
||||||
Foreign currency contracts
|
Other current assets
|
$
|
161
|
|
$
|
(89
|
)
|
$
|
72
|
|
Commodity contracts
|
Other current assets
|
31
|
|
(5
|
)
|
26
|
|
|||
Commodity contracts
|
Deferred charges and other assets
|
57
|
|
(4
|
)
|
53
|
|
|||
Total
|
|
$
|
249
|
|
$
|
(98
|
)
|
$
|
151
|
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
||||||
Foreign currency contracts
|
Other current assets
|
$
|
29
|
|
$
|
(15
|
)
|
$
|
14
|
|
Commodity contracts
|
Other current assets
|
8
|
|
(1
|
)
|
7
|
|
|||
Commodity contracts
|
Deferred charges and other assets
|
4
|
|
(2
|
)
|
2
|
|
|||
Total
|
|
$
|
41
|
|
$
|
(18
|
)
|
$
|
23
|
|
Total asset derivatives
|
|
$
|
290
|
|
$
|
(116
|
)
|
$
|
174
|
|
|
|
|
|
|
||||||
Liability derivatives:
|
|
|
|
|
||||||
Derivatives designated as hedging instruments:
|
|
|
|
|
||||||
Interest rate swaps
|
Other noncurrent obligations
|
$
|
181
|
|
$
|
—
|
|
$
|
181
|
|
Foreign currency contracts
|
Accrued and other current liabilities
|
98
|
|
(89
|
)
|
9
|
|
|||
Commodity contracts
|
Accrued and other current liabilities
|
93
|
|
(6
|
)
|
87
|
|
|||
Commodity contracts
|
Other noncurrent obligations
|
60
|
|
(8
|
)
|
52
|
|
|||
Total
|
|
$
|
432
|
|
$
|
(103
|
)
|
$
|
329
|
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
||||||
Foreign currency contracts
|
Accrued and other current liabilities
|
$
|
20
|
|
$
|
(15
|
)
|
$
|
5
|
|
Commodity contracts
|
Accrued and other current liabilities
|
8
|
|
(4
|
)
|
4
|
|
|||
Commodity contracts
|
Other noncurrent obligations
|
7
|
|
(3
|
)
|
4
|
|
|||
Total
|
|
$
|
35
|
|
$
|
(22
|
)
|
$
|
13
|
|
Total liability derivatives
|
|
$
|
467
|
|
$
|
(125
|
)
|
$
|
342
|
|
1.
|
Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between TDCC and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.
|
Fair Value of Derivative Instruments
|
Dec 31, 2018
|
|||||||||
In millions
|
Balance Sheet Classification
|
Gross
|
Counterparty and Cash Collateral Netting
1
|
Net Amounts Included in the Consolidated Balance Sheet
|
||||||
Asset derivatives:
|
|
|
|
|
||||||
Derivatives designated as hedging instruments:
|
|
|
|
|
||||||
Foreign currency contracts
|
Other current assets
|
$
|
98
|
|
$
|
(42
|
)
|
$
|
56
|
|
Commodity contracts
|
Other current assets
|
47
|
|
(13
|
)
|
34
|
|
|||
Commodity contracts
|
Deferred charges and other assets
|
18
|
|
(3
|
)
|
15
|
|
|||
Total
|
|
$
|
163
|
|
$
|
(58
|
)
|
$
|
105
|
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
||||||
Foreign currency contracts
|
Other current assets
|
$
|
128
|
|
$
|
(64
|
)
|
$
|
64
|
|
Commodity contracts
|
Other current assets
|
41
|
|
(1
|
)
|
40
|
|
|||
Commodity contracts
|
Deferred charges and other assets
|
4
|
|
(2
|
)
|
2
|
|
|||
Total
|
|
$
|
173
|
|
$
|
(67
|
)
|
$
|
106
|
|
Total asset derivatives
|
|
$
|
336
|
|
$
|
(125
|
)
|
$
|
211
|
|
|
|
|
|
|
||||||
Liability derivatives:
|
|
|
|
|
||||||
Derivatives designated as hedging instruments:
|
|
|
|
|
||||||
Interest rate swaps
|
Other noncurrent obligations
|
$
|
64
|
|
$
|
—
|
|
$
|
64
|
|
Foreign currency contracts
|
Accrued and other current liabilities
|
46
|
|
(42
|
)
|
4
|
|
|||
Commodity contracts
|
Accrued and other current liabilities
|
111
|
|
(18
|
)
|
93
|
|
|||
Commodity contracts
|
Other noncurrent obligations
|
86
|
|
(9
|
)
|
77
|
|
|||
Total
|
|
$
|
307
|
|
$
|
(69
|
)
|
$
|
238
|
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
||||||
Foreign currency contracts
|
Accrued and other current liabilities
|
$
|
103
|
|
$
|
(64
|
)
|
$
|
39
|
|
Commodity contracts
|
Accrued and other current liabilities
|
7
|
|
(4
|
)
|
3
|
|
|||
Commodity contracts
|
Other noncurrent obligations
|
8
|
|
(3
|
)
|
5
|
|
|||
Total
|
|
$
|
118
|
|
$
|
(71
|
)
|
$
|
47
|
|
Total liability derivatives
|
|
$
|
425
|
|
$
|
(140
|
)
|
$
|
285
|
|
1.
|
Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between TDCC and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.
|
Basis of Fair Value Measurements on a Recurring Basis
|
Mar 31, 2019
|
Dec 31, 2018
|
||||||||||||||||
Quoted Prices in Active Markets for Identical Items
(Level 1) |
Significant Other Observable Inputs
(Level 2) |
Total
|
Quoted Prices in Active Markets for Identical Items
(Level 1) |
Significant Other Observable Inputs
(Level 2) |
Total
|
|||||||||||||
In millions
|
||||||||||||||||||
Assets at fair value:
|
|
|
|
|
|
|
||||||||||||
Cash equivalents
1
|
$
|
—
|
|
$
|
345
|
|
$
|
345
|
|
$
|
—
|
|
$
|
566
|
|
$
|
566
|
|
Marketable securities
|
—
|
|
101
|
|
101
|
|
—
|
|
100
|
|
100
|
|
||||||
Equity securities
2
|
21
|
|
—
|
|
21
|
|
16
|
|
—
|
|
16
|
|
||||||
Debt securities:
2
|
|
|
|
|
|
|
||||||||||||
Government debt
3
|
—
|
|
702
|
|
702
|
|
—
|
|
700
|
|
700
|
|
||||||
Corporate bonds
|
19
|
|
1,054
|
|
1,073
|
|
—
|
|
983
|
|
983
|
|
||||||
Derivatives relating to:
4
|
|
|
|
|
|
|
||||||||||||
Foreign currency
|
—
|
|
189
|
|
189
|
|
—
|
|
226
|
|
226
|
|
||||||
Commodities
|
10
|
|
90
|
|
100
|
|
17
|
|
93
|
|
110
|
|
||||||
Total assets at fair value
|
$
|
50
|
|
$
|
2,481
|
|
$
|
2,531
|
|
$
|
33
|
|
$
|
2,668
|
|
$
|
2,701
|
|
Liabilities at fair value:
|
|
|
|
|
|
|
||||||||||||
Long-term debt including debt due within one year
5
|
$
|
—
|
|
$
|
20,850
|
|
$
|
20,850
|
|
$
|
—
|
|
$
|
20,214
|
|
$
|
20,214
|
|
Derivatives relating to:
4
|
|
|
|
|
|
|
||||||||||||
Interest rates
|
—
|
|
181
|
|
181
|
|
—
|
|
64
|
|
64
|
|
||||||
Foreign currency
|
—
|
|
117
|
|
117
|
|
—
|
|
149
|
|
149
|
|
||||||
Commodities
|
13
|
|
155
|
|
168
|
|
23
|
|
189
|
|
212
|
|
||||||
Total liabilities at fair value
|
$
|
13
|
|
$
|
21,303
|
|
$
|
21,316
|
|
$
|
23
|
|
$
|
20,616
|
|
$
|
20,639
|
|
1.
|
Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" in the consolidated balance sheets and held at amortized cost, which approximates fair value.
|
2.
|
TDCC’s investments in debt securities, which are primarily available-for-sale, and equity securities are included in “Other investments” in the consolidated balance sheets.
|
3.
|
U.S. Treasury obligations, U.S. agency obligations, agency mortgage-backed securities and other municipalities’ obligations.
|
4.
|
See Note
15
for the classification of derivatives in the consolidated balance sheets.
|
5.
|
See Note
15
for information on fair value measurements of long-term debt.
|
Assets and Liabilities of Consolidated VIEs
|
Mar 31,
2019 |
Dec 31,
2018 |
||||
In millions
|
||||||
Cash and cash equivalents
|
$
|
109
|
|
$
|
82
|
|
Other current assets
|
116
|
|
114
|
|
||
Net property
|
718
|
|
734
|
|
||
Other noncurrent assets
|
60
|
|
45
|
|
||
Total assets
1
|
$
|
1,003
|
|
$
|
975
|
|
Current liabilities
|
$
|
318
|
|
$
|
334
|
|
Long-term debt
|
43
|
|
75
|
|
||
Other noncurrent obligations
|
46
|
|
31
|
|
||
Total liabilities
2
|
$
|
407
|
|
$
|
440
|
|
1.
|
All assets were restricted at
March 31, 2019
and
December 31, 2018
.
|
2.
|
All liabilities were nonrecourse at
March 31, 2019
and
December 31, 2018
.
|
Carrying Amounts of Assets and Liabilities Related to Nonconsolidated VIEs
|
|
Mar 31,
2019 |
Dec 31,
2018 |
||||
In millions
|
Description of asset or liability
|
||||||
Hemlock Semiconductor L.L.C.
|
Equity method investment
1
|
$
|
(658
|
)
|
$
|
(495
|
)
|
Silicon joint ventures
|
Equity method investments
2
|
$
|
96
|
|
$
|
100
|
|
AgroFresh Solutions, Inc.
|
Equity method investment
2
|
$
|
45
|
|
$
|
48
|
|
Other receivable
3
|
$
|
8
|
|
$
|
8
|
|
1.
|
Classified as "Other noncurrent obligations" in the consolidated balance sheets. TDCC's maximum exposure to loss was
zero
at
March 31, 2019
(
zero
at
December 31, 2018
).
|
2.
|
Classified as "Investment in nonconsolidated affiliates" in the consolidated balance sheets.
|
3.
|
Classified as "Accounts and notes receivable - Other" in the consolidated balance sheets.
|
Balances Due To or Due From DuPont and its Affiliates
|
Mar 31, 2019
|
Dec 31, 2018
|
||||
In millions
|
||||||
Accounts and notes receivable - Other
|
$
|
201
|
|
$
|
288
|
|
Accounts payable - Other
|
$
|
112
|
|
$
|
201
|
|
Sales to DuPont and its Affiliates
|
Three Months Ended
|
|||||
In millions
|
Mar 31, 2019
|
Mar 31, 2018
|
||||
Net sales
|
$
|
106
|
|
$
|
43
|
|
Cost of sales
|
$
|
65
|
|
$
|
26
|
|
•
|
1.6 million
stock options with a weighted-average exercise price of
$54.89
and a weighted-average fair value of
$7.99
per share;
|
•
|
1.7 million
restricted stock units with a weighted-average fair value of
$54.89
per share; and
|
•
|
1.2 million
performance stock units with a weighted-average fair value of
$57.58
per share.
|
Selected Financial Data
|
Three Months Ended
|
|||||
In millions
|
Mar 31,
2019 |
Mar 31,
2018 |
||||
Net sales
|
$
|
13,582
|
|
$
|
14,899
|
|
|
|
|
||||
Cost of sales ("COS")
|
$
|
10,707
|
|
$
|
11,552
|
|
Percent of net sales
|
78.8
|
%
|
77.5
|
%
|
||
|
|
|
||||
Research and development expenses ("R&D")
|
$
|
361
|
|
$
|
386
|
|
Percent of net sales
|
2.7
|
%
|
2.6
|
%
|
||
|
|
|
||||
Selling, general and administrative expenses ("SG&A")
|
$
|
701
|
|
$
|
751
|
|
Percent of net sales
|
5.2
|
%
|
5.0
|
%
|
||
|
|
|
||||
Effective tax rate
|
31.7
|
%
|
20.9
|
%
|
||
|
|
|
||||
Net income available for common stockholder
|
$
|
541
|
|
$
|
1,342
|
|
Sales Variances by Geographic Region
|
Three Months Ended Mar 31, 2019
|
|||||||||
Local Price & Product Mix
|
Currency
|
Volume
|
Portfolio & Other
|
Total
|
||||||
Percentage change from prior year
|
||||||||||
U.S. & Canada
|
(7
|
)%
|
—
|
%
|
(4
|
)%
|
—
|
%
|
(11
|
)%
|
EMEA
1
|
(7
|
)
|
(5
|
)
|
1
|
|
(1
|
)
|
(12
|
)
|
Asia Pacific
|
(9
|
)
|
(2
|
)
|
9
|
|
—
|
|
(2
|
)
|
Latin America
|
(10
|
)
|
(1
|
)
|
2
|
|
—
|
|
(9
|
)
|
Total
|
(8
|
)%
|
(2
|
)%
|
1
|
%
|
—
|
%
|
(9
|
)%
|
1.
|
Europe, Middle East and Africa.
|
Cash Flow Summary
|
Three Months Ended
|
|||||
In millions
|
Mar 31, 2019
|
Mar 31, 2018
|
||||
Cash provided by (used for):
|
|
|
||||
Operating activities
|
$
|
1,426
|
|
$
|
(158
|
)
|
Investing activities
|
(486
|
)
|
(92
|
)
|
||
Financing activities
|
(667
|
)
|
(853
|
)
|
||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
30
|
|
100
|
|
||
Summary
|
|
|
||||
Increase (Decrease) in cash, cash equivalents and restricted cash
|
$
|
303
|
|
$
|
(1,003
|
)
|
Cash, cash equivalents and restricted cash at beginning of period
|
2,709
|
|
6,207
|
|
||
Cash, cash equivalents and restricted cash at end of period
|
$
|
3,012
|
|
$
|
5,204
|
|
Less: Restricted cash and cash equivalents, included in "Other current assets"
|
43
|
|
18
|
|
||
Cash and cash equivalents at end of period
|
$
|
2,969
|
|
$
|
5,186
|
|
Cash Flows from Operating Activities Excluding Impact of ASU 2016-15 and Additional Interpretive Guidance (non-GAAP)
|
Three Months Ended
|
||
In millions
|
Mar 31, 2018
|
||
Cash flows from operating activities - Updated for impact of ASU 2016-15 and additional interpretive guidance (GAAP)
|
$
|
(158
|
)
|
Less: Impact of ASU 2016-15 and additional interpretive guidance
|
445
|
|
|
Cash flows from operating activities - Excluding impact of ASU 2016-15 and additional interpretive guidance (non-GAAP)
|
$
|
287
|
|
Total Debt
|
Mar 31, 2019
|
Dec 31, 2018
|
||||
In millions
|
||||||
Notes payable
|
$
|
317
|
|
$
|
305
|
|
Long-term debt due within one year
|
2,369
|
|
340
|
|
||
Long-term debt
|
17,160
|
|
19,254
|
|
||
Gross debt
|
$
|
19,846
|
|
$
|
19,899
|
|
- Cash and cash equivalents
|
2,969
|
|
2,669
|
|
||
- Marketable securities
|
101
|
|
100
|
|
||
Net debt
|
$
|
16,776
|
|
$
|
17,130
|
|
Gross debt as a percent of total capitalization
|
41.4
|
%
|
41.6
|
%
|
||
Net debt as a percent of total capitalization
|
37.3
|
%
|
38.0
|
%
|
Credit Ratings
|
Long-Term Rating
|
Short-Term Rating
|
Outlook
|
Standard & Poor’s
|
BBB
|
A-2
|
Stable
|
Moody’s Investors Service
|
Baa2
|
P-2
|
Stable
|
Fitch Ratings
|
BBB+
|
F2
|
Stable
|
Contractual Obligations at Mar 31, 2019
|
Payments Due In
|
|
|||||||||||||
In millions
|
2019
|
2020-2021
|
2022-2023
|
2024 and beyond
|
Total
|
||||||||||
Long-term debt obligations
1
|
$
|
2,307
|
|
$
|
6,088
|
|
$
|
2,007
|
|
$
|
9,451
|
|
$
|
19,853
|
|
Expected cash requirements for interest
2
|
$
|
673
|
|
$
|
1,629
|
|
$
|
1,168
|
|
$
|
6,907
|
|
$
|
10,377
|
|
Operating leases
|
$
|
437
|
|
$
|
936
|
|
$
|
634
|
|
$
|
1,157
|
|
$
|
3,164
|
|
1.
|
Excludes unamortized debt discount and issuance costs of $324 million. Includes finance lease obligations of $369 million. Assumes the option to extend will be exercised for
$2.5 billion
of the Dow Silicones Term Loan Facility.
|
2.
|
Cash requirements for interest on long-term debt was calculated using current interest rates at March 31, 2019, and includes $4,919 million of various floating rate notes.
|
Asbestos-Related Claim Activity
|
2019
|
2018
|
||
Claims unresolved at Jan 1
|
12,780
|
|
15,427
|
|
Claims filed
|
1,383
|
|
1,932
|
|
Claims settled, dismissed or otherwise resolved
|
(1,569
|
)
|
(3,026
|
)
|
Claims unresolved at Mar 31
|
12,594
|
|
14,333
|
|
Claimants with claims against both Union Carbide and Amchem
|
(4,509
|
)
|
(5,148
|
)
|
Individual claimants at Mar 31
|
8,085
|
|
9,185
|
|
Dow Inc.
The Dow Chemical Company and Subsidiaries
PART II – OTHER INFORMATION
|
|
EXHIBIT NO.
|
|
DESCRIPTION
|
|
|
Separation and Distribution Agreement, dated as of April 1, 2019, by and among Corteva, Inc., Dow Inc. and DowDuPont Inc. (incorporated by reference to Exhibit 2.1 to Dow Inc.'s Current Report on Form 8-K filed with the SEC on April 2, 2019).
|
|
|
|
Amended and Restated Certificate of Incorporation of Dow Inc. (incorporated by reference to Exhibit 3.1 to Dow Inc.’s Current Report on Form 8-K filed with the SEC on April 2, 2019).
|
|
|
|
Amended and Restated Bylaws of Dow Inc. (incorporated by reference to Exhibit 3.2 to Dow Inc.’s Current Report on Form 8-K filed with the SEC on April 2, 2019).
|
|
|
4.3
|
|
Dow Inc. agrees to provide the SEC, on request, copies of all other such indentures and instruments that define the rights of holders of long-term debt of Dow Inc. and its consolidated subsidiaries, including The Dow Chemical Company, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K.
|
|
|
Tax Matters Agreement, dated as of April 1, 2019, by and among DowDuPont Inc., Dow Inc., and Corteva, Inc. (incorporated by reference to Exhibit 10.1 to Dow Inc.’s Current Report on Form 8-K filed with the SEC on April 2, 2019).
|
|
|
|
Employee Matters Agreement, dated as of April 1, 2019, by and among DowDuPont Inc., Dow Inc., and Corteva, Inc. (incorporated by reference to Exhibit 10.2 to Dow Inc.’s Current Report on Form 8-K filed with the SEC on April 2, 2019).
|
|
|
|
MatCo/SpecCo Intellectual Property Cross License Agreement, dated as of April 1, 2019, by and between Dow Inc. et al and DowDuPont Inc. et al (incorporated by reference to Exhibit 10.3 to Dow Inc.’s Current Report on Form 8‑K filed with the SEC on April 2, 2019).
|
|
|
|
MatCo/AgCo Intellectual Property Cross License Agreement, dated as of April 1, 2019, by and between Dow Inc. et al and Corteva, Inc. et al (incorporated by reference to Exhibit 10.4 to Dow Inc.’s Current Report on Form 8-K filed with the SEC on April 2, 2019).
|
|
|
|
Dow Inc. 2019 Stock Incentive Plan effective as of April 1, 2019 (incorporated by reference to Exhibit 4.4 to Dow Inc.’s Registration Statement on Form S-3, filed with the SEC on April 1, 2019).
|
|
|
|
Form of Performance Stock Unit Award Agreement under the Dow Inc. 2019 Stock Incentive Plan effective as of April 1, 2019 (incorporated by reference to Exhibit 4.4.1 to Dow Inc.’s Registration Statement on Form S-3, filed with the SEC on April 1, 2019).
|
|
|
|
Form of Restricted Stock Award Agreement under the Dow Inc. 2019 Stock Incentive Plan effective as of April 1, 2019 (incorporated by reference to Exhibit 4.4.2 to Dow Inc.’s Registration Statement on Form S-3, filed with the SEC on April 1, 2019).
|
|
|
|
Form of Restricted Stock Unit Award Agreement under the Dow Inc. 2019 Stock Incentive Plan effective as of April 1, 2019 (incorporated by reference to Exhibit 4.4.3 to Dow Inc.’s Registration Statement on Form S-3, filed with the SEC on April 1, 2019).
|
|
|
|
Form of Stock Appreciation Right Award Agreement under the Dow Inc. 2019 Stock Incentive Plan effective as of April 1, 2019 (incorporated by reference to Exhibit 4.4.4 to Dow Inc.’s Registration Statement on Form S-3, filed with the SEC on April 1, 2019).
|
|
|
|
Form of Stock Option Award Agreement under the Dow Inc. 2019 Stock Incentive Plan effective as of April 1, 2019 (incorporated by reference to Exhibit 4.4.5 to Dow Inc.’s Registration Statement on Form S-3, filed with the SEC on April 1, 2019).
|
|
|
|
Form of Restricted Stock Unit Award Agreement (Director) under the Dow Inc. 2019 Stock Incentive Plan effective as of April 1, 2019 (incorporated by reference to Exhibit 4.4.6 to Dow Inc.’s Registration Statement on Form S-3, filed with the SEC on April 1, 2019).
|
|
|
10.8
*
|
|
The Dow Chemical Company Elective Deferral Plan (Pre-2005), restated and effective as of April 1, 2019.
|
|
|
The Dow Chemical Company Elective Deferral Plan (Post 2004), restated and effective as of April 1, 2019 (incorporated by reference to Exhibit 4.1 to The Dow Chemical Company’s Registration Statement on Form S-8 POS, filed with the SEC on April 1, 2019).
|
|
|
10.10
*
|
|
Dow Inc. Voluntary Deferred Compensation Plan for Non-Employee Directors, restated and effective as of April 1, 2019.
|
|
23
*
|
|
Ankura Consulting Group, LLC's Consent.
|
|
31.1
*
|
|
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
*
|
|
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1
*
|
|
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2
*
|
|
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
|
XBRL Instance Document.
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document.
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
Dow Inc.
The Dow Chemical Company and Subsidiaries
Signature
|
/s/ RONALD C. EDMONDS
|
Ronald C. Edmonds
|
Controller and Vice President
|
of Controllers and Tax
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|